TXOne Networks Introduces Breakthrough Capability for Intelligent Vulnerability Mitigation in New Release of TXOne SageOne
4.6.2025 04:00:00 CEST | Business Wire | Press Release
TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, today announced an expanded new version of its SageOne OT Cybersecurity Governance Platform. Already relied upon by many industrial leaders across sectors with exacting cybersecurity requirements, TXOne SageOne has been enhanced to deliver a novel capability for intelligent vulnerability mitigation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603632277/en/
One of the most common challenges faced by (operational technology) OT cybersecurity practitioners is how to patch effectively under time constraints—making risk-based prioritization essential. TXOne SageOne uniquely integrates external intelligence on emerging threats, the specific operational context of each manufacturer and industry-standard vulnerability scoring to provide meaningful, tailored guidance to the organization’s security team. The TXOne Networks solution implements a rigorous, three-phase approach to risk-based vulnerability management:
- Assess—TXOne SageOne pulls deep, OS-level vulnerability and configuration data—augmented by real-time threat intelligence—to build an accurate, context-rich view of every CPS asset’s true risk exposure.
- Prioritize—Asset criticality, observed attack patterns and existing defenses are fused into TXOne Networks’ proprietary Vulnerability Situational Awareness Rating (VSAR) risk score to distill thousands of potential flaws to the few that truly demand attention.
- Remediate—TXOne SageOne automatically interprets each asset’s context (device type, operational status and business impact) and prescribes the optimal mitigation path (full patching, virtual patching or just-In-time guided micro-segmentation) without disrupting production.
CPS consist of mission-critical assets and sophisticated computation and shutting down a production line to implement a patch on such a system or to undertake other protective measures in the OT network generally is not an option. Conventional cybersecurity management platforms rely on vulnerability scoring that is predicated on concepts and protocols borrowed from information technology (IT). That information is useful in OT cybersecurity—but impractical if relied upon alone. Conventional systems often indicate thousands of high-priority vulnerabilities across a large-scale manufacturing environment. A security team tasked with securing OT often is no more than 10 people, so the practical reality is the majority of alerts generated by today’s conventional systems go unaddressed.
TXOne SageOne, however, narrows guidance to a manageable number of legitimately critical vulnerabilities that demand immediate action across a given manufacturer’s OT threat landscape. Armed with a holistic, dependable overview of the truly urgent threats to its corporate environment, the security team is positioned to immediately take concrete, meaningful steps to protect people, OT assets and processes.
“TXOne SageOne represents a breakthrough in OT security governance, having been conceived and purpose-built from the ground up to address the unique cybersecurity needs of OT networks and systems—not IT,” said Dr. Terence Liu, CEO of TXOne Networks. “The latest release introduces intelligent vulnerability mitigation capabilities that underscore this differentiation, empowering security teams with tools tailored to the specific nature of OT environments and delivering actionable insights that lead to achievable, impactful outcomes.”
All of TXOne Networks’ industry-leading point products for CPS security are centrally controlled via the SageOne platform—Stellar for endpoint protection, Element for security inspection and Edge for network defense. As the central hub for all TXOne Networks security offerings, SageOne brings Element, Stellar, and Edge into seamless collaboration to deliver unified visibility, centralized control and optimized vulnerability management. TXOne SageOne provides a comprehensive, detailed and easy-to-understand visualization of the precise security posture of operations at any given moment.
For more information on TXOne SageOne, please visit https://www.txone.com/products/cps-protection-platform/txone-sageone/.
Follow TXOne Networks on Blog, Twitter, and LinkedIn.
About TXOne Networks
TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603632277/en/
Contacts
Global Media Contacts
Lynette Lee
lynette.lee@txone.com
Minu Seshasayee
Interprose for TXOne Networks Americas
minu_seshasayee@interprosepr.com
+1 425.283.7426
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom